Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani Purchases 9,289 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani acquired 9,289 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were acquired at an average price of $2.15 per share, with a total value of $19,971.35. Following the completion of the transaction, the chief financial officer now directly owns 44,500 shares in the company, valued at approximately $95,675. This trade represents a 26.38 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $2.28 on Thursday. The firm has a market cap of $73.37 million, a price-to-earnings ratio of -5.85 and a beta of 0.82. The stock has a 50-day simple moving average of $2.86 and a 200-day simple moving average of $3.03. Anixa Biosciences, Inc. has a 52-week low of $2.07 and a 52-week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities research analysts predict that Anixa Biosciences, Inc. will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the business. Westside Investment Management Inc. raised its holdings in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences during the 3rd quarter valued at about $34,000. Tyler Stone Wealth Management lifted its holdings in Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the last quarter. International Assets Investment Management LLC boosted its position in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the period. Finally, Concorde Asset Management LLC acquired a new position in Anixa Biosciences during the second quarter valued at approximately $31,000. 29.13% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on ANIX shares. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.